Capecitabine
Capecitabine is an orally administered antimetabolite prodrug that is enzymatically converted to 5-fluorouracil (5-FU) within tumor cells. Its active metabolites, FdUMP and FUTP, inhibit DNA and RNA synthesis, respectively, making it a key tool for in vitro and in vivo cancer research, particularly in studies of colorectal, breast, and gastric malignancies.
Product Specifications
CAS Number
154361-50-9
Product Name Alternative
DNASynthesis, DNA Synthesis, DNA/RNA Synthesis, Analog, Apoptosis, Capecitabine, Capecitibine, Capiibine, inhibit, NucleosideAntimetabolite, Nucleoside Antimetabolite/Analog, Nucleoside Antimetabolite, Inhibitor, Thymidine phosphorylase, Xeloda, RNASynthesis, RO 09-1978, RNA Synthesis
Field of Research
Cell Biology, Molecular Biology, Pharmacology & Drug Discovery
Purity
99.37% (May vary between batches)
Solubility
5% DMSO+95% Saline:1.8 mg/mL (5.01 mM) ; PBS:50 mg/mL (139.14 mM) ; Ethanol:35.9 mg/mL (99.9 mM) ; DMSO:242 mg/mL (673.44 mM)
Smiles
O[C@H]1[C@@H] (O[C@H] (C) [C@H]1O) N2C (=O) N=C (NC (OCCCCC) =O) C (F) =C2
Molecular Formula
C15H22FN3O6
Molecular Weight
359.35
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
126014 50 µg
DR5 (Death Receptor 5, CD262, HGNC:11905, KILLER, TNF-related Apoptosis-inducing Ligand Receptor 2, TRAIL Receptor 2, TRAILR2, TRAIL-R2, TRICK2, TRICK2A, TRICK2B, TRICKB, Tumor Necrosis Factor Receptor Superfamily Member 10B, TNFRSF10B, UNQ160/PRO186, ZTNFR9)
Sign In for Pricing
View Details